Burjeel aims to carry out more clinical trials in the UAE and boost cancer care
Abu Dhabi healthcare company Burjeel Holdings is aiming to do more clinical trials in the UAE, as it seeks to boost its oncology and paediatric services, its chairman has said. A total of 25 clinical trials have been either completed or are under way by the company. These include a multicentre study of the efficacy and safety of the drug Mitapivat for patients with thalassaemia, an inherited blood disorder, as well as trials in oncology. In April, the Department of Health Abu Dhabi also said it had successfully completed a clinical trial in collaboration with Swedish company Cellcolabs and Burjeel Holdings to evaluate cell-based therapies for degenerative joint diseases. 'Clinical trials are coming up – it's about seeing the opportunity, inviting pharma here, because clinical trials have never happened outside [the traditional hubs]. So we are opening up a new horizon,' Dr Shamsheer Vayalil, founder and chairman of Burjeel Holdings, told The National at the Make it in the Emirates event in Abu Dhabi. 'But for that, you need the clinical strength … We have it now, and we are adding on to it. It's a constantly evolving process, but we have made a lot of progress,' Dr Vayalil added. There is already 'huge' global interest in the region, he said. Earlier in May, it was announced that the UAE will host the first clinical trials outside the US of a wireless brain chip made by tech billionaire Elon Musk's Neuralink company. The chip is designed to improve the lives of paralysed people. The Department of Health Abu Dhabi said it had teamed up with Cleveland Clinic Abu Dhabi and Neuralink to launch the trial programme, known as UAE-PRIME. 'Health care should become a way of enabling the economy,' Dr Vayalil said. 'We want to improve the GDP. We want to bring clinical trials. We want to bring in research. We want to train doctors. We want this to become a mode of enabling an economy. 'We have interest in trials, we have interest in pharma, we have interest in innovation. So that's how we look at health care. I think health care should move more into solutions.' Burjeel Holdings this week also revealed more details of its healthcare logistics joint venture with AD Ports Group, called Docktour. The platform is focused on addressing Africa's healthcare challenges and will facilitate the deployment of modular healthcare units, including container-based hospitals and clinics. It will also help to set up full-service medical infrastructure, including field hospitals and permanent facilities. Docktour will also provide emergency response capabilities and support local capacity-building through clinical training. The joint venture will partner with national health ministries, international NGOs, and UAE-led humanitarian initiatives to provide services. 'I think this is going to be something that will disrupt [the market] … it's a local solution for a global problem,' Dr Vayalil said. 'What is the problem today? It is the reach, logistics, manpower. We work in remote sites. For us, the growth should come from deserving places as well, meaningful growth.' However, he also stressed that the company focuses on 'bankable projects' and that their plan with Docktour was long-term. 'I'm not too worried about where the bill will come. We are talking to various organisations. We are making a model which is very compulsive. We are going to show governments how they can save on the cost,' he said. Abu Dhabi-listed Burjeel Holding this month reported a 64 per cent drop in first quarter net profit attributable to shareholders to reach Dh36.37 million ($9.9 million), although revenue rose by 5.7 per cent to Dh1.27 billion. Revenue growth was driven by a 5.3 per cent annual increase in patient footfall. The company said it was hit by a 'number of operational challenges, with group performance impacted by a sharper-than-anticipated slowdown in March and delays in the conversion of complex care programmes'. The hiring of niche specialists is one reason that quarterly earnings were affected, Dr Vayalil said. 'You hire a hemato-oncologist, who is not a regular physician … he takes a while to settle down, the referral system needs to fall in place. So, we are deliberately taking certain decisions which are time-consuming, because if I only look at the balance sheet and [quarter to quarter], we're not going to be meaningful. We always say that it's the net result versus the Q-to-Q,' he said. The company is focusing heavily on cancer care and building the practice. In April, it partnered with US non-profit Caring Cross to locally manufacture CAR T-cell therapies at up to 90 per cent less than current international costs, estimated to range from $350,000 to more than $1 million. CAR-T therapies reprogramme a patient's immune cells to attack cancer cells and are being used to treat blood cancers such as leukaemia and lymphoma. Caring Cross will support with the technology, materials and specialised training to establish a local system. 'We don't want to be a supermarket of health care, we want to be a boutique. Ultimately, we want to be known for certain things. Cancer is top of our stuff, as well as paediatrics,' Dr Vayalil said. The company is considering further expansion in Africa and other emerging markets, he said, but did not provide any specifics. Dr Vayalil also said Burjeel is focused on using technology to support physicians. 'We don't want to take a position of replacing the doctor,' he said. 'If you ask me about five-year growth, I would not be able to even define and tell you precisely, but if our execution ability would prevail, I think we will make lot of noise in the right direction.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
7 hours ago
- Al Etihad
DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi
20 June 2025 22:37 BOSTON (WAM) Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership during the BIO International Convention in Boston agreement aims to localise the manufacturing of pharmaceuticals in Abu Dhabi and advance digital health Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said, 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences." She added, "By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.'The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development his part, Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, said, 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi." Bachir added, "Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.'Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 - 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).
Khaleej Times
10 hours ago
- Khaleej Times
The rise of Red Light Therapy in Dubai: A high-tech alternative to cosmetic surgery?
Beauty treatments and cosmetic procedures have long been associated with the world of luxury but as treatments become more technology-focused, it is becoming ever easier to keep a grasp of youthful looks well into old age. A surgeon's nip and tuck here and there was once sidelined for the rich and famous of Hollywood and the silver screen. But with people now prepared to admit to cosmetic procedures as a status symbol, spending on appearance has become a more acceptable side of modern life. The benefits of longevity therapies, like stem cell treatments and hyperbaric oxygen chambers, are growing by the day, leading even more of the beauty conscious towards scientific innovation to retain that youthful glow. Red Light Therapy — a form of infrared technology long associated with muscle recovery and physical benefits — has taken a firm foothold in Dubai's beauty industry as a bonafide, less invasive alternative to cosmetic surgery. Paired with a healthy lifestyle, improved muscle tone, energy boosts and an overall feel-good glow can be delivered from a visit to the many 'red rooms' now popping up across the city at dedicated wellness clinics and resorts. With potential for improved blood circulation, pain relief and even hair growth stimulated by the powers of low-energy red or near-infrared light, the power-boost delivered to the body's energy cells has the potential for a myriad of health benefits. An important point, Dr Giuseppe Bellucci, a longevity expert at the Baldan Group, told KT LUXE, is the heat delivered by RLT is significantly different to the high environmental temperatures of Dubai's searing summer. 'Unlike the ambient heat of the city — especially during heatwaves — which can be quite overwhelming due to the 'urban heat island' effect, InfraBaldan 3.0 delivers targeted and adjustable thermotherapy, optimising treatment effectiveness in maximum comfort,' he said. 'After the session, clients typically experience increased energy and overall wellbeing, thanks to the combination of infrared therapy and gentle physical activity.' InfraBaldan 3.0 uses targeted therapeutic heating to restore optimal body temperature, promoting the reactivation of blood and lymphatic circulation. It also provides an exercise function, with an in-built cycling machine to encourage blood circulation during the therapy to maximise its effect to users who are seated in a small capsule, similar in appearance to the cockpit of a fighter jet. The result, developers claim, is an improvement in physiological muscle tone and strengthening of the immune system, which is particularly vulnerable to temperature fluctuations. The therapy works by stimulating collagen production, increasing blood circulation, and reducing inflammation, bringing potential benefits to skin conditions and other medical areas. Meanwhile, better blood flow induced by RLT promotes overall tissue health throughout the body. And by stimulating fibroblasts — cells that formulate our connective tissue — red light boosts collagen production, potentially reducing wrinkles, laughter lines and overall skin texture that is more typically ironed out with botox or fillers. While this kind of therapy is nothing new, its application into the cosmetic industry is proving a growing market for those opting for less invasive procedures. InfraBaldan was born in the 1990s as a pioneering system for natural weight loss through the use of infrared technology combined with moderate physical activity. Over time, it has undergone continuous technological evolution, with a renewed focus on enhancing effectiveness, safety and user experience bringing treatments into the surging longevity health space. The 3.0 next-generation infrared technology utilises specific wavelengths for optimal tissue penetration, targeting basal metabolism and precision lipolysis, or the metabolic breakdown of fat. The capsule's synergistic cardio system integrates light physical activity, with careful monitoring of heart rate parameters to ensure maximum safety, while treatments can be personalised via a digital interface to track each session and an individual's improvements. By tracking a user's biometrics, such as heart rate, the therapy becomes more relaxing and effective through each session by reducing the naturally occurring stress hormone, cortisol. 'The key feature of the InfraBaldan 3.0 system is the intelligent synergy between infrared technology and controlled physical activity, made possible by an integrated heart rate sensor,' said Dr Bellucci. This seemingly simple component marks a major leap forward compared to traditional infrared treatments, which are often static and generalised. 'Synchronising the action of infrared rays with heart rate introduces an advanced level of bio-adaptation to the treatment, helping to reduce physiological stress, stimulate vagal tone and relaxation, and lower cortisol levels.' By also synchronising breathing patterns, respiratory quality improves, delivering a double-whammy of health benefits to the user. With greater oxygen availability in the tissues, proper oxidation of fatty acids occurs, helping burn fat fast by prioritising it as an energy source. Infrared technology is clearly having a moment, with hand-held personal devices and at-home red solariums becoming more affordable, and of higher quality, to deliver life-boosting therapies at home. In-clinic costs for RLT can vary, with sessions in Dubai ranging from Dh50 to Dh270, making it an affordable option for skincare and general wellbeing. Many clinics offer discounts for multiple visits when compared with a single session, which can last anywhere from five minutes to half an hour, depending on individual requirements and their sensitivity. From face marks, to hand-held devices and full-body RLT solarium beds and sleeping bags — the treatments available at home are wide-ranging and offer a multitude of personal options. Improvements in the light wavelength and power delivered by personal devices have also made investments in the technology attractive for some. Longer wavelengths can be optimised for deeper tissue penetration to power-up the therapeutic benefits for conditions like joint pain and muscle recovery. Increasingly, the technology is utilising the powers of artificial intelligence to track usage and monitor improvements. The results are adding a growing body of research and data to prove the positive affects of RLT across multiple areas of health and wellbeing, in a booming cosmetic market. Australia-based Bon Charge is a company looking to expand into the Middle East through its range of infrared sauna blankets and other RLT devices. 'People are actually starting to wake up a little bit to the efficacy of red light therapy,' said Andy Bant, founder and CEO of Bon Charge. 'They're starting to realise not all devices are created equal and are looking for reputable companies, brands and thought leaders out there to educate on this topic a little bit more,' he added. 'They're probably the reason why we're seeing it moving away from the salons and more into the home.' RLT technology continues to reveal more insights into its positive effects, as well as promoting the natural production of feel-good chemicals into the bloodstream. 'If you're looking at something like acne, for instance, chemical pills are quite invasive and abrasive on the skin,' said Mr Bant. 'But using red light therapy on an ongoing basis, you could actually reduce the appearance of acne. If you're looking at more cosmetic procedures, such as to reduce wrinkles and fine lines, that's also a really big benefit of using a red light face mask or a big red light panel.'
Arabian Business
13 hours ago
- Arabian Business
DoH and Sanofi partner to develop new global vaccines in Abu Dhabi
The Department of Health – Abu Dhabi (DoH) and Sanofi, one of the world's leading biopharma companies, will team up to develop new global vaccines and strengthen regional capabilities in vaccine manufacturing. The two organisations signed a memorandum of understanding to this effect at the BIO International Convention 2025, in Boston, USA, recently. Dr Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi, and Laurie Gery, Global Head of Business Development, Vaccines at Sanofi, were present at the signing ceremony. DoH and Sanofi strengthen health collaboration The collaboration will leverage Abu Dhabi's health-tech ecosystem and advanced research infrastructure and Sanofi's research and development expertise. It reflects Abu Dhabi's goal to establish the emirate as a leading centre for bio- and pharmaceutical innovation. Both entities will collaborate to streamline regulatory processes, enhance manufacturing preparedness, and foster knowledge sharing among local and international experts. View this post on Instagram A post shared by دائرة الصحة – أبوظبي "DoH" (@dohsocial) Dr Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH, commented: 'DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis, and conducting parallel clinical trial phases. 'By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships. Abu Dhabi offers a globally connected, purpose-driven environment for leading research, and together we will drive a transformative change that will safeguard the health and well-being of our community while contributing to global health security.' Both organisations will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. DoH and Sanofi are collaborating in other areas as well. In 2022, the two parties agreed to work on four strategic healthcare priorities, including hematology and oncology, rare metabolic diseases, diabetes management and vaccines. Baptiste de Clarens, General Manager Greater Gulf, Vaccines, Sanofi, added: 'The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership. 'This agreement allows us to examine how Sanofi's experience in vaccine development could complement Abu Dhabi's growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation.'
